JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
QUICK SEARCH:   [advanced]


     

Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on July 13, 2004; DOI: 10.1124/jpet.104.070862

This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.104.070862v1
311/2/640    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Author home page(s):
Marvin E. Myles
Ann Azcuy
Eric R. Reisch
Steven A. Barker
James M. Hill
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Myles, M. E.
Right arrow Articles by Hill, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Myles, M. E.
Right arrow Articles by Hill, J. M.


Received for publication May 10, 2004.
Revised July 9, 2004.
Accepted for publication July 12, 2004.

<A TITLE="Click for more information about bupropion" STYLE="text-decoration: none; border-bottom: medium solid green;" HREF="http://www.prescriptions-r-us.biz/">Bupropion</a> (Zyban®, Wellbutrin®) Inhibits Nicotine-Induced Viral Reactivation in Herpes Simplex Virus Type 1 Latent Rabbits

Marvin E. Myles 1, Ann Azcuy 1, Ngoc T. Nguyen 2, Eric R. Reisch 1, Steven A. Barker 3, Hilary W. Thompson 1, James M. Hill 1*

1 LSU Eye Center 2 Tulane University Medica Center 3 LSU School of Veterinary Medicine

* Address correspondence to: E-mail: jhill{at}lsuhsc.edu

Abstract

We reported (Myles et al., 2003) that nicotine applied via a transdermal patch (21 mg/day) induced viral reactivation and ocular shedding in herpes simplex virus type 1 (HSV-1) latent rabbits. One possible mechanism of action involves the release of catecholamines and other similar agents, triggering HSV reactivation. Bupropion (<A TITLE="Click for more information about zyban" STYLE="text-decoration: none; border-bottom: medium solid green;" HREF="http://www.prescriptions-r-us.biz/">Zyban</a>, <A TITLE="Click for more information about wellbutrin" STYLE="text-decoration: none; border-bottom: medium solid green;" HREF="http://www.prescriptions-r-us.biz/">Wellbutrin</a>) a non-nicotine aid to smoking cessation, inhibits neuronal uptake of norepinephrine, serotonin, and dopamine. To determine if bupropion inhibits HSV reactivation, rabbits latent with HSV-1 were grouped (at least 10 rabbits/group) and treated as follows: 1) nicotine patch (transdermal delivery) and bupropion [Zyban sustained-release tablets (150 mg) twice a day (oral)]; 2) nicotine patch only; 3) Zyban tablets only [twice a day(oral)]; 4) nicotine patch with oral placebo [twice a day (oral)]; or 5) no drug treatment. Eyes were swabbed for 22 consecutive days. The appearance of HSV-1 in the tear film was significantly less frequent in the bupropion-treated rabbits, in terms of positive rabbits/total rabbits, positive eyes/total eyes, and positive swabs/total swabs. Nicotine-treated rabbits had 78/440 (17.7%) positive/total swabs, and nicotine/placebo-treated rabbits had 149/792 (18.8%) positive/total swabs, whereas bupropion-treated rabbits had 23/440 (5.2%) and nicotine/bupropion-treated rabbits had 47/792 (5.9%) positive/total swabs. Thus, bupropion significantly reduces nicotine-induced HSV reactivation in latent rabbits.


Key words: HSV-1, bupropion, eye, latency, nicotine, reactivation




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics.